Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics
- 1.8k Downloads
Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
KeywordsMucositis Toxicity Chemotherapy-induced gut toxicity Cancer side effects Zinc sulphate Palifermin R-spondin1 Benzydamine hydrochloride (HCl) Probiotics Antimicrobials Antioxidants Analgesics Coating agents Mucositis treatment
Compliance with Ethics Guidelines
Conflict of Interest
Ysabella Z.A. Van Sebille declares that she has no conflict of interest.
Romany Stansborough declares that he has no conflict of interest.
Hannah R. Wardill declares that she has no conflict of interest.
Emma Bateman has received support through a grant from Entera Health.
Rachel J. Gibson has received support through a grant from Onyx Pharmaceuticals and has also received compensation from Onyx Pharmaceuticals for service as a consultant.
Dorothy M. Keefe has received research funding through grants from Helsinn, Pfizer and Entera Health and has also received compensation from Helsinn and Munipharma for serving on speakers’ bureaus.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2(1):21-32. discussion 35-6.Google Scholar
- 5.Cirillo M et al. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2009;20(12):1929–35.CrossRefGoogle Scholar
- 6.Sonis S. et al. Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer. 2014.Google Scholar
- 13.••Lalla RV et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61. This paper reviewed the available literature and produced evidence based guidelines for the management of patients with mucositis, impacting clinical practice.PubMedCentralCrossRefPubMedGoogle Scholar
- 22.•Raber-Durlacher JE et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):343–55. This paper provided evidence based guidelines for the use of growth factors, including palifermin, in patients with mucositis.CrossRefPubMedGoogle Scholar
- 37.•Sheibani KM et al. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J Clin Oncol. 2015;11(1):22–7. This paper provided evidence on the efficacy of benzydamine HCl in the prevention of radiation induced oral mucositis.CrossRefPubMedGoogle Scholar
- 45.Stringer AM et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood). 2007;232(1):96–106.Google Scholar
- 51.Sorensen JB et al. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer. 2008;112(7):1600–6.CrossRefPubMedGoogle Scholar
- 55.Bensadoun RJ et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112(1):204–11.CrossRefPubMedGoogle Scholar
- 63.Leenstra JL et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014;32(15):1571–7.PubMedCentralCrossRefPubMedGoogle Scholar
- 66.Vokurka S et al. The effect of polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair) on oral microbial colonization and pain control compared with other rinsing solutions in patients with oral mucositis after allogeneic stem cells transplantation. Med Sci Monit. 2011;17(10):CR572–6.PubMedCentralCrossRefPubMedGoogle Scholar
- 72.Schubert MM et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15(10):1145–54.CrossRefPubMedGoogle Scholar